The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Treatment of exudative age-related macular degeneration has been significantly improved by
the advent of Lucentis™( which provides improved vision rather than simply stabilization) is
common; however, monthly injections may be required to maintain this effect. It is
hypothesized that sustained release fluocinolone acetonide will allow maintenance of the
improved vision with fewer Lucentis injections.